Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Avoiding premature licensing

A Corrigendum to this article was published on 01 February 2007

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1: Value of biotech out-licensing deals.
Figure 2: Example of a collaborative development financing structure.
Figure 3: Illustrative value creation through collaborative development financing.

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

As a result of the financings completed by Symphony Capital Partners and its affiliates listed in Table 1, Mark Kessel and Sam Hall have certain economic interests in the biotech companies listed therein and the respective collaborative partnering companies developing those indications.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kessel, M., Hall, S. Avoiding premature licensing. Nat Rev Drug Discov 5, 985–986 (2006). https://doi.org/10.1038/nrd2203

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2203

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing